SLC5A2 and type 2 diabetes mellitus: It is the first study to include exclusively early low-risk type 2 diabetes patients with normoalbuminuria, assessing the early tubular protective effects of SGLT2 inhibitors and evaluating the dual regulatory effects of empagliflozin on blood glucose and lipids.